Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 20, 2019 | Series B | $25M | 1 | ARCH Venture Partners | — | Detail |
Sep 3, 2015 | Series A | $30M | 1 | — | — | Detail |
Jul 23, 2014 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | Yes | Series B |